JP6014655B2 - うつ病および不安を予防し治療するためのタペンタドール - Google Patents

うつ病および不安を予防し治療するためのタペンタドール Download PDF

Info

Publication number
JP6014655B2
JP6014655B2 JP2014506793A JP2014506793A JP6014655B2 JP 6014655 B2 JP6014655 B2 JP 6014655B2 JP 2014506793 A JP2014506793 A JP 2014506793A JP 2014506793 A JP2014506793 A JP 2014506793A JP 6014655 B2 JP6014655 B2 JP 6014655B2
Authority
JP
Japan
Prior art keywords
pain
tapentadol
depression
anxiety
score
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014506793A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014516935A (ja
Inventor
シュタイガーヴァルト・イローナ
ヤーネル・ウルリヒ
ツシェントケ・トーマス
Original Assignee
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング filed Critical グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング
Publication of JP2014516935A publication Critical patent/JP2014516935A/ja
Application granted granted Critical
Publication of JP6014655B2 publication Critical patent/JP6014655B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2014506793A 2011-04-29 2012-04-27 うつ病および不安を予防し治療するためのタペンタドール Expired - Fee Related JP6014655B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11003508 2011-04-29
EP11003508.6 2011-04-29
PCT/EP2012/001819 WO2012146383A1 (en) 2011-04-29 2012-04-27 Tapentadol for preventing and treating depression and anxiety

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016183088A Division JP2017031182A (ja) 2011-04-29 2016-09-20 うつ病および不安を予防し治療するためのタペンタドール

Publications (2)

Publication Number Publication Date
JP2014516935A JP2014516935A (ja) 2014-07-17
JP6014655B2 true JP6014655B2 (ja) 2016-10-25

Family

ID=44260882

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014506793A Expired - Fee Related JP6014655B2 (ja) 2011-04-29 2012-04-27 うつ病および不安を予防し治療するためのタペンタドール
JP2016183088A Pending JP2017031182A (ja) 2011-04-29 2016-09-20 うつ病および不安を予防し治療するためのタペンタドール
JP2017163838A Expired - Fee Related JP6445637B2 (ja) 2011-04-29 2017-08-29 うつ病および不安を予防し治療するためのタペンタドール

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016183088A Pending JP2017031182A (ja) 2011-04-29 2016-09-20 うつ病および不安を予防し治療するためのタペンタドール
JP2017163838A Expired - Fee Related JP6445637B2 (ja) 2011-04-29 2017-08-29 うつ病および不安を予防し治療するためのタペンタドール

Country Status (15)

Country Link
US (3) US20120277319A1 (enExample)
EP (3) EP2701693B1 (enExample)
JP (3) JP6014655B2 (enExample)
CY (2) CY1119586T1 (enExample)
DK (2) DK3272343T3 (enExample)
ES (2) ES2788548T3 (enExample)
HR (2) HRP20171570T1 (enExample)
HU (2) HUE049308T2 (enExample)
LT (2) LT2701693T (enExample)
NO (1) NO2701693T3 (enExample)
PL (2) PL3272343T3 (enExample)
PT (2) PT2701693T (enExample)
RS (2) RS56523B1 (enExample)
SI (2) SI2701693T1 (enExample)
WO (1) WO2012146383A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
ES2428938T3 (es) 2009-07-22 2013-11-12 Grünenthal GmbH Forma de dosificación resistente a la manipulación y estabilizada frente a la oxidación
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
PL2736497T3 (pl) 2011-07-29 2018-01-31 Gruenenthal Gmbh Tabletka odporna na ingerencję, zapewniająca natychmiastowe uwalnianie leku
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
EP2845625A1 (en) * 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
WO2015078891A1 (en) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
PT3302454T (pt) * 2015-05-26 2021-04-01 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Composições para utilização no tratamento da doença de parkinson e distúrbios associados
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US10292948B2 (en) * 2017-01-11 2019-05-21 Torrent Pharmaceuticals Limited Tapentadol nasal composition

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
CA2620364A1 (en) 2005-08-26 2007-03-01 David C. Yeomans Methods for treatment of headaches by administration of oxytocin
US20090306050A1 (en) 2006-02-03 2009-12-10 Timothy Dinan Treatment and prevention of depression with pain, depression secondary to pain, and of neuropathic pain
PL2012763T3 (pl) 2006-04-28 2011-08-31 Gruenenthal Gmbh Kombinacja farmaceutyczna zawierająca 3-(3-dimetyloamino-1-etylo-2-metylo-propylo)-fenol i NSAID
DE102007012165A1 (de) 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
CN102065852B (zh) 2007-11-23 2015-06-17 格吕伦塔尔有限公司 他喷他多组合物
US20100297181A1 (en) 2007-12-26 2010-11-25 Eisai R&D Management Co., Ltd. AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ
US7872046B2 (en) 2008-01-25 2011-01-18 Xenoport, Inc. Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
WO2010100477A2 (en) 2009-03-03 2010-09-10 Shire Llc Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
MX2011011442A (es) 2009-04-30 2011-11-18 Gruenenthal Gmbh Uso de compuestos de 1-fenil-3-dimetilaminopropano para tratar dolor reumatoide.
FR2970261B1 (fr) 2011-01-10 2013-05-03 IFP Energies Nouvelles Procede d'hydrotraitement de charges lourdes d'hydrocarbures avec des reacteurs permutables incluant au moins une etape de permutation progressive
EP2694049B1 (en) 2011-04-05 2018-10-31 Grünenthal GmbH Tapentadol for preventing chronification of pain

Also Published As

Publication number Publication date
RS60152B1 (sr) 2020-05-29
PT2701693T (pt) 2017-11-16
LT3272343T (lt) 2020-05-11
JP2017031182A (ja) 2017-02-09
CY1123051T1 (el) 2021-10-29
PT3272343T (pt) 2020-04-23
JP2014516935A (ja) 2014-07-17
CY1119586T1 (el) 2018-03-07
NO2701693T3 (enExample) 2018-01-20
SI2701693T1 (sl) 2017-11-30
EP3656380A1 (en) 2020-05-27
PL2701693T3 (pl) 2018-01-31
EP3272343B1 (en) 2020-02-12
DK2701693T3 (da) 2017-11-13
US20150018426A1 (en) 2015-01-15
EP2701693A1 (en) 2014-03-05
PL3272343T3 (pl) 2020-07-27
SI3272343T1 (sl) 2020-06-30
WO2012146383A1 (en) 2012-11-01
EP3272343A1 (en) 2018-01-24
HUE034003T2 (en) 2018-02-28
RS56523B1 (sr) 2018-02-28
DK3272343T3 (da) 2020-04-27
JP2018021053A (ja) 2018-02-08
LT2701693T (lt) 2017-11-10
JP6445637B2 (ja) 2018-12-26
US20170196822A1 (en) 2017-07-13
HRP20200600T1 (hr) 2020-10-16
EP2701693B1 (en) 2017-08-23
US9980927B2 (en) 2018-05-29
US20120277319A1 (en) 2012-11-01
HUE049308T2 (hu) 2020-09-28
HRP20171570T1 (hr) 2017-11-17
ES2788548T3 (es) 2020-10-21
ES2646363T3 (es) 2017-12-13

Similar Documents

Publication Publication Date Title
JP6445637B2 (ja) うつ病および不安を予防し治療するためのタペンタドール
JP5933176B2 (ja) タペンタドールの用量調節
TWI663971B (zh) 猝倒症之治療
JP5796959B2 (ja) 関節炎における痛みの治療のためのタペンタドール
US12090148B2 (en) Treatment of migraine
WO2013063289A1 (en) Pharmaceutical compositions for treating pain
KR20080055967A (ko) 섬유 근육통 증후군의 장기 치료를 위한 밀라시프란
CN105764510A (zh) H3受体拮抗剂与胆碱酶抑制剂组合用于阿尔茨海默氏病治疗中的用途
JP2019142932A (ja) 疼痛の慢性化を予防するためのタペンタドール
CN109310669A (zh) 氨基甲酸酯化合物用于预防或治疗三叉神经痛的用途
CN120659601A (zh) 用于治疗瘙痒的诺卡酮
CN114980874B (zh) 肌痛性脑脊髓炎/慢性疲劳症候群治疗剂
WO2024196957A1 (en) Method for treating l-dopa-induced dyskinesia using befiradol
TW202440106A (zh) 用於治療勃起障礙之化合物
TW201919597A (zh) 利用新斯的明（neostigmine）及nk-1拮抗劑治療重症肌無力之醫藥組合物及方法
WO2015188005A1 (en) Novel (r)-isometheptene compositions and uses

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160712

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160831

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160926

R150 Certificate of patent or registration of utility model

Ref document number: 6014655

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees